TransThera Sciences (Nanjing), Inc. 2025 Annual Report: Detailed Analysis for Investors

Key Highlights from the 2025 Annual Report

• Successful Listing on the HKEX: TransThera Sciences (Nanjing), Inc. (“TransThera” or “the Company”) was officially listed on the Main Board of the Hong Kong Stock Exchange (HKEX) on 23 June 2025, marking a significant milestone in the Company’s history and opening up access to global capital.
• Financial Performance:
  • Revenue: The Company had no commercialized product in 2025; therefore, no revenue was recorded.
  • Net Loss: The Company reported a net loss of RMB 295.96 million for the year ended 31 December 2025, compared to a net loss of RMB 274.61 million in 2024. Loss per share was RMB 0.76.
  • Research and Development (R&D) Spending: R&D costs remained high and slightly increased by 1% to RMB 246.76 million, reflecting the Company’s continued investment in its drug pipeline.
  • Administrative Expenses: Administrative expenses rose by 15% to RMB 54.78 million, mainly due to additional expenditures arising from the HKEX listing and associated professional service fees.
  • Other Income and Gains: Other income and gains dropped sharply by 48.6% year-on-year, primarily due to reduced interest income and fewer government grants.
  • Debt and Gearing: The Company reported no bank loans or borrowings as of 31 December 2025. The gearing ratio increased to 31.11% (from 19.92%), and the debt-to-asset ratio rose to 23.7% (from 16.6%), reflecting higher liabilities relative to assets, likely due to increased operating expenses and listing costs.
  • Cash Position: The Company maintained a net current asset position of RMB 371.32 million and net assets of RMB 416.38 million as at 31 December 2025.
• Drug Development Pipeline and Progress:
  • Tinengotinib: The Company’s lead candidate, Tinengotinib, achieved a key milestone by being included in the List of Products for Priority Review by the CDE of China. The new drug application was accepted, and the product is on the verge of commercialization in China. An international multi-center Phase III clinical trial in cholangiocarcinoma (CCA) is also progressing steadily.
• Shareholder and Corporate Governance Matters:
  • No dividend was declared or paid in 2025, reflecting the Company’s continued pre-profit status and accumulated losses.
  • As required by PRC law, future dividends can only be considered after accumulated losses are offset and sufficient net profit is allocated to statutory reserves.
  • Shareholder rights, communication policies, and internal control frameworks have been strengthened. No significant legal proceedings or contingent liabilities were reported during the year.
  • The Company’s public float has remained above the minimum required by HKEX rules since listing.
  • The Supervisory Committee reported no material non-compliance, and both the Board and management were diligent in their duties.
• Capital Moves and Events After Reporting Period:
  • On 13 January 2026, the Company entered into a placing agreement for up to 2,100,000 new shares at HK\$92.85 per share, completed on 20 January 2026. This capital raising effort is potentially price sensitive and demonstrates confidence in further funding the pipeline.
• Risks and Uncertainties:
  • The Company remains pre-revenue, with significant ongoing R&D expenses and no guarantee of product commercialization.
  • The drug development process is inherently lengthy, expensive, and uncertain. Failure to achieve regulatory approval or to commercialize products could significantly impact future prospects and share value.
  • Intellectual property protection, competition from other pharmaceutical companies, and the ability to build effective commercialization capabilities remain key risks.
• Major Shareholders and Insider Interests:
  • Dr. Frank Wu, Chairman and CEO, holds a significant combined interest in the Company, amounting to about 32.97% of the total shares, including both direct shareholding and interests through controlled entities.
  • Other major institutional investors include Genecare Development Limited, Morningside Venture, PharmaBlock Sciences, and several PRC-based funds.
• Employee Incentive and Share-Based Payments:
  • The Company expanded its share incentive schemes, with a new plan in 2023 granting 10,674,066 restricted shares to employees and replacing outstanding options. These incentives are designed to retain and motivate key talent as the Company prepares for commercialization.
• Internal Controls, ESG, and Compliance:
  • The Company reported no non-compliance incidents or material legal proceedings. Anti-corruption and insider information controls are in place and have been reviewed by the Board and Audit Committee.
  • Environmental, Social, and Governance (ESG) policies are in force, with a focus on minimizing environmental impact and strict adherence to PRC and Hong Kong regulations.

Potentially Price-Sensitive and Shareholder-Relevant Issues

• Listing and Subsequent Share Placement: The successful HKEX listing and subsequent share placement at a high price may impact share liquidity, valuation, and investor sentiment positively, especially as proceeds will support R&D and commercialization efforts.
• Pipeline Milestones: Tinengotinib’s progress towards commercialization in China and ongoing Phase III international trials are critical catalysts. Any regulatory approvals or data readouts could significantly move the share price.
• Financial Risks: Ongoing net losses and lack of current revenue mean that further capital raising may be needed, potentially diluting existing shareholders. Investors should watch for future funding announcements or partnership deals.
• Dividend Policy: No dividends are expected in the near term due to accumulated losses and required statutory reserve allocations. Investors seeking income should factor this into their risk assessment.

Summary for Investors

The 2025 Annual Report of TransThera Sciences (Nanjing), Inc. underscores a pivotal year marked by a successful HKEX listing, strong continued investment in drug development, and significant pipeline progress, particularly with its lead candidate Tinengotinib. However, the Company remains loss-making and is yet to generate revenue, which, together with ongoing capital needs and the inherent risk in drug development, should be carefully considered by investors. The share placement after year-end and the Company’s robust governance and compliance processes are notable positives, while the absence of dividends and reliance on future commercialization are key risks.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. All forward-looking statements and price-sensitive information are based on the best available data from the Company’s public disclosures as of the reporting period. Investors should conduct their own due diligence and consult with professional advisors before making investment decisions.

View TRANSTHERA-B Historical chart here